Press Releases DBV Technologies

Equities

DBV

FR0010417345

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2025-07-08 EDT			5-day change	1st Jan Change
1.856 ^EUR	+0.76%		+16.44%	+194.60%

07-08	European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading	MT
07-07	European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	MT

Press Releases

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old	06-25	GL
DBV Technologies to Participate in Upcoming EAACI Congress 2025	06-12	GL
AGM 2025: ATTENDANCE SUMMARY REPORT (DBV 2025 ARRETE DE FEUILLE DE PRESENCE EN)	06-12	PU
AGM 2025: Results of the AGM votes (DBV 2025 RESULTAT DES VOTES EN)	06-12	PU
AGM 2025: Quorum (DBV 2025 QUORUM DEFINITF EN)	06-12	PU
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting	06-11	GL
DBV Technologies : Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025	06-04	PU
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document	06-03	GL
Combined General Meeting of June 11, 2025	05-15	GL
Combined General Meeting of June 11, 2025	05-15	AQ
DBV Technologies : Statutory Auditors’ report on 34th resolution (DBV AGM2025 reso 34 Rapport CAC emission reservee salaries PEE revu DPPEN RC)	05-14	PU
DBV Technologies : Statutory Auditors report on the 2025 regulated agreements (Statutory Auditors report on the 2025 regulated agreements EN)	05-14	PU
DBV Technologies : Statutory Auditors’ report on resolutions 22nd to 32nd (DBV AGM2025 reso 22 a 32 Rapport CAC emissions delegation globale revu DPPEN RC)	05-14	PU
DBV Technologies : Statutory Auditors’ report on 21st resolution (DBV AGM2025 reso 21 Rapport CAC reduction de capital revu DPPEN)	05-14	PU
DBV Technologies : Statutory Auditors’ report on 35th resolution (DBV AGM2025 reso 35 Rapport CAC BSA BSAANE BSAAR revu DPPEN RC)	05-14	PU
DBV Technologies : Statutory Auditors’ report on 36th resolution (DBV AGM2025 reso 36 Rapport CAC AGA salaries et mandataires revu DPPEN RC)	05-14	PU
DBV Technologies : Statutory Auditors’ report on 37th resolution (DBV AGM2025 reso 37 Rapport CAC OSA salaries et mandataires revu DPPEN RC)	05-14	PU
DBV Technologies : Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025	05-07	PU
DBV Technologies : Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025	05-07	PU
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference	05-05	GL
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference	05-05	AQ
DBV Technologies Reports First Quarter 2025 Financial Results	04-30	GL
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document	04-11	GL
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document	04-11	AQ
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved	03-27	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases DBV Technologies

Equities

DBV

FR0010417345

Pharmaceuticals

Press Releases

Filters